Printer Friendly

FDA ADVISORY PANEL RECOMMENDS APPROVAL OF MEDTRONIC PCD DEVICE

 FDA ADVISORY PANEL RECOMMENDS APPROVAL OF MEDTRONIC PCD DEVICE
 MINNEAPOLIS, Feb. 3 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT), said today that the circulatory systems advisory panel of the U.S. Food and Drug Administration has unanimously recommended the Medtronic Pacer Cardioverter Defibrillator (PCD) (TM) device for approval by the agency.
 FDA panels, comprised of physicians and other specialists knowledgeable about medical or technical issues related to devices under consideration, advise the agency as it processes applications for subsequent commercial approval.
 Medtronic officials were pleased by the panel's recommendation. The PCD, which has been in clinical trials since 1989, is an implantable device designed to offer staged therapy to treat tachyarrhythmia -- an abnormally fast heartbeat.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 2/3/92
 /CONTACT: (Investor) Dale Beumer, 612-574-3038, or (Media) Dick Reid, 612-574-3052/
 (MDT) CO: Medtronic, Inc. ST: Minnesota IN: MTC SU:


AL -- MN005 -- 6194 02/03/92 12:25 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:165
Previous Article:MOBIL SELECTS WORLD VISION FOR $100,000 AFRICA GRANT
Next Article:WELLS FARGO INTRODUCES 'ONE CALL' FOR SMALL BUSINESS OWNERS; BUSINESSES CAN SAVE TIME, ANY TIME, 24 HOURS A DAY
Topics:


Related Articles
PANEL CONSIDERATION DOUBTFUL FOR MEDTRONIC PCD DEVICE AT NOVEMBER MEETING
PCD LEAD SYSTEM REQUIRING NO MAJOR CHEST SURGERY IS RELEASED BY MEDTRONIC IN EUROPE
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC PCD DEVICE AT FEBRUARY MEETING
MEDTRONIC AGREES TO ACQUIRE CARDIORHYTHM, ENTERS ABLATION MARKET
MEDTRONIC EARNINGS INCREASE 21.1 PCT. ON STRONG MARKET SHARE TRENDS
MEDTRONIC, VENTRITEX ANNOUNCE AGREEMENT TO CROSS-LICENSE TACHYARRHYTHMIA PATENTS
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC TRANSVENE LEADS AT MEETING IN AUGUST
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF LESS-INVASIVE LEADS FOR PCD SYSTEM
MEDTRONIC RELEASES FIRST COMPLETE TRANSVENOUS TIERED-THERAPY SYSTEM FOR TREATMENT OF TACHYARRHYTHMIA
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC RF CARDIAC ABLATION SYSTEM AT MEETING DECEMBER 5

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters